Coping with Job Lock

 

When you're unable to take a new job because your new employer's insurer refuses to cover certain preexisting conditions, including cancer, that's called "job lock." It reduces your job mobility and may limit your income potential.

Many people once found themselves in that predicament if they, or someone in their family, was in cancer treatment. One study of Indiana workers who had health insurance through their employers found that chronic illness reduced their job mobility by about 40 percent.

Yet you may be more fearful about job lock than is warranted. In 1997, the federal Health Insurance Portability and Accountability Act (HIPAA) was passed. It limits the exclusions for preexisting conditions. As a result, if you are in a group health plan now and are moving to a job that has coverage with another group health plan, the new insurer cannot refuse you coverage because of cancer or other preexisting conditions. This often requires that you have little or no gap in coverage, such as being uninsured for 63 days or more.

Job lock protection under HIPAA covers group health plans in every U.S. state, but each state interprets the law differently. Some will allow a "group of one" category.

Plan carefully before switching jobs:

  • Contact your state's health insurance assistance program to make sure that you won't be left uncovered.
  • Ask your current employer for a "certificate of creditable coverage" to verify that the group plan is covered under HIPAA.
  • If you're leaving to become self-employed, you may have to meet special criteria to retain coverage.
  • Haven't decided what you want to do? Make sure you have COBRA, or some sort of continuation coverage, to keep your HIPAA protection against preexisting condition clauses.
Latest Cancer News
ACOG Updates Cervical Cancer Screening Guidelines

November 20, 2009 — The American College of Obstetricians and Gynecologists (ACOG) has revised its cervical cancer screening recommendations: the organization now recommends that women begin screening at the age of 21 and receive screening at less frequent intervals. These recommendations will be published in the December 2009 issue of Obstetrics and Gynecology.

New VelcadeĀ®-melphalan Transplant Regimen for Multiple Myeloma

November 20, 2009 — Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.

Folic Acid May Be Beneficial in Patients with Recurrent Colorectal Adenoma Who Are Folate Deficient

November 20, 2009 — Researchers affiliated with the Health Professional Follow-Up Study and the Nurses’ Health Study have reported that folic acid supplementation in patients with recurrent colorectal adenoma was not protective or harmful in most patients. However, patients who were folate deficient had a significant 39% decrease in adenoma recurrence. The details of this study appeared in an early online publication on October 28, 2009 in the American Journal of Clinical Nutrition.

Select news items provided by Reuters Health